Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,570.00
Ask: 1,680.00
Change: 0.00 (0.00%)
Spread: 110.00 (7.006%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,599.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: US Stocks To Open Cautiously Higher, Earnings In Focus

Wed, 23rd Jul 2014 11:49

LONDON (Alliance News) - US stocks are set to open cautiously higher Wednesday, boosted by the the lack of consensus among EU leaders to impose sector-wide sanctions on the Russian economy, but muted in trepidation of a raft of corporate earnings.

Currently, the DJIA, the S&P 500, and the Nasdaq Composite all look set to open about 0.1% higher.

Investors have had a mixed reaction to the big technology stock earnings released after the market close Tuesday. Apple shares are 0.5% lower in the pre-market despite beating earnings per share expectations as sales were slightly lighter than expected, while Microsoft shares are about 1.5% higher after it announced its own numbers.

The focus will remain on US earnings, particularly the biotechnology and social media stocks given Fed Chair Janet Yellen's recent comments that valuations in those particular sectors look "stretched." All eyes will be on Facebook the company reports after the US closing bell.

"While the Federal Reserve is perhaps not the best source of equity analysis the comments do highlight the importance of today’s earnings reports from Biogen, Gilead Sciences and Facebook in justifying overall stock market valuations," said CMC Markets market analyst Jasper Lawler.

Pepsico has done what its soft drink rival Coca-Cola failed to do on Tuesday and impressed the market with its second quarter results, announcing earnings per share of USD1.32, ahead of the consensus expectation of USD1.23. Pepsico shares are moving higher in the premarket.

Amid a heightened focus on the airline after it decided to cancel all flights to Tel-Aviv on Tuesday due to a rocket exploding near the airport, Delta Airlines has reported second quarter earnings per share of USD0.94, up from USD0.8 a year earlier.

The US followed Delta's decision with a short-term ban on all flights to Tel-Aviv's Ben Gurion airport, although that didn't stop Secretary of State John Kerry landing there earlier Wednesday to attempt to advance ceasefire talks as the death toll from the conflict nears 650. The longer a flight ban to Tel-Aviv lasts, the greater the pressure on the US to broker a solution, both from the perspective of the economic effect on Israel, and frustrated US-Israelis and influential American Jews. Former New York Mayor Michael Bloombeg issued a statement Wednesday saying, "the flight restrictions are a mistake that hand Hamas an undeserved victory and should be lifted immediately."

US MBS mortgage applications jumped 2.4% in the week ended July 18, after falling 3.6% in the previous week. The only other release of note in the data calendar Wednesday is the eurozone consumer confidence index at 1500 BST, which is expected to remain unchanged in July at negative 7.5.

Ahead of the US opening bell, UK stocks are continuing to trade modestly higher, with the FTSE 100 up 0.2% at 6,806.01, the FTSE 250 up 0.3% at 15,697.82, and the AIM All-share up 0.1% at 773.07.

GlaxoSmithKline has dropped to the bottom of the FTSE 100, down 2.9%, after reporting a drop in first-half pretax profit to GBP1.89 billion from GBP2.70 billion in the previous year. Group revenue was also down to GBP11.17 billion from GBP13.1 billion. Glaxo said that full-year core earnings per share is now expected to be broadly similar to 2013.

Bank of England Governor Mark Carney has been speaking at a business conference in Glasgow ahead of the opening of the Commonwealth Games there, and following the release of the the latest BoE meeting minutes earlier Wednesday. After beginning with a games pun about the UK economy being the current holder of "fastest growing advanced economy in the world title," Carney went on to put the quarterly inflation report, due next month, squarely in focus for central bank watchers.

The BoE chief reiterated his recent message that real wage growth is now the key indicator as to when rates will rise, and that currently there are conflicting messages in the labour market, namely that unemployment is rapidly falling, but wage growth is stagnant.

"A key judgement for the MPC is when and to what extent these developments will translate into real wage growth, and in turn that wage growth into price pressures," Carney said. "Next month's Inflation Report provides the next opportunity to update our thinking on these important questions."

Carney also reiterated that the main risk to the UK economic recovery is an overheating of the housing market and the prospect of UK households indebtedness, which he used as one of the explanations for future rate rises being gradual.


By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.